Synapto is an early stage biotech company revolutionizing Alzheimer's diagnosis through portable EEG and Machine Learning.
The device works by analyzing a patient's brainwave by using a variety of mathematical analyses and compares it to known healthy and Alzheimer's brainwave biomarkers. Using machine learning characterization, the algorithm can then decide, to a certain level of confidence whether the new brainwave belongs to an Alzheimer's patient or a healthy control patient.
A portable Electroencephalogram records highly sensitive electrical signals in the brain, which can then be analyzed using our mathematical biomarkers and analyses. This recording then allows the models to predict the severity and progression of the disease. Synapto is utilizing portable EEG from OpenBCI, making our device unique in that it is smaller, affordable, and more effective than current diagnostic measures.
Synapto’s project serves as a prime example of how tomorrow’s bioengineers are working today to find solutions to some of the most significant health challenges our society faces
This represents a monumental achievement, not simply for the engineering community, but for the wider world of human health research.
I think the device is unique and will prove to be the first line of testing in the future for detection of Alzheimer disease.